3rd Generation Tankless Inhaled Nitric Oxide System Gets FDA Approval
The US FDA has approved the third Generation Genosyl Delivery System, a tankless inhaled nitric oxide (iNO) therapy device, according to manufacturer Vero Biotech Inc.
The US FDA has approved the third Generation Genosyl Delivery System, a tankless inhaled nitric oxide (iNO) therapy device, according to manufacturer Vero Biotech Inc.
Genzyme's Xenpozyme was approved for pediatric and adult patients with Acid Sphingomyelinase Deficiency (ASMD) a rare genetic disease that causes premature death due to neurologic and respiratory complications.
The FDA has expanded the approval for Merck's Vaxneuvance for prevention of invasive disease caused by Streptococcus pneumoniae to include children 6 weeks through 17 years of age.
Brensocatib did not improve the clinical status of patients hospitalized with severe SARS-CoV-2 infection in the double-blind randomized, placebo-controlled STOP-COVID19 multicenter clinical trial, according to research presented at ATS 2022.
Children age 5-through-11 are now authorized to receive the Pfizer COVID booster at least five months after completion of their primary two-dose series of the Pfizer vaccine.
An expanded ACTIV-6 study will test 600 mcg/kg of ivermectin daily for six days in patients who have had a positive COVID-19 test within the past 10 days, and have at least two symptoms of the illness for no more than seven days.